Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Behav Sleep Med. 2019 May 2;18(3):406–419. doi: 10.1080/15402002.2019.1604344

Table 3.

Linear Regressions Predicting Mental Health Outcomes (at 12-month follow-up) from Sleep Quality Trajectory, N = 505

Outcome 1:
Depression
Outcome 2:
Anxiety
Outcome 3:
Self-Efficacy for Condom Use
ARR p 95% CI ARR p 95% CI ARR p 95% CI
Constant 1.11 .34 [0.89, 1.38] 1.03 .82 [0.83, 1.27] 0.82 .10 [0.65, 1.04]
Age 1.00 .69 [0.99, 1.01] 1.00 .90 [0.99, 1.01] 1.00 .81 [0.99, 1.01]
Race and Ethnicity (ref. White)
 Black or Hispanic/Latino 0.85 .05 [0.73, 1.00] 0.91 .26 [0.78, 1.07] 1.27 <.01 [1.07, 1.51]
Study Arm (ref. Control)
 Intervention 1.10 .21 [0.95, 1.29] 1.12 .14 [0.96, 1.30] 1.10 .25 [0.93, 1.31]
Relationship Status (ref. Single)
 Partnered 0.86 .08 [0.73, 1.02] 0.96 .65 [0.82, 1.13] 1.17 .10 [0.97, 1.40]
Viral Load at Screener (ref. Undetectable)
 Detectable (≥200 copies) 1.06 .58 [0.87, 1.29] 1.06 .55 [0.87, 1.29] 1.15 .19 [0.93, 1.43]
Education (ref. Less than college)
 College degree or more 0.87 .10 [0.74, 1.03] 0.90 .20 [0.76, 1.06] 1.04 .71 [0.86, 1.24]
Income (ref. less than $20K)
 $20K - $49,999 0.93 .46 [0.77, 1.12] 0.88 .16 [0.73, 1.06] 1.16 .14 [0.95, 1.42]
 $50K or more 0.87 .22 [0.69, 1.09] 0.84 .12 [0.61, 1.05] 1.01 .91 [0.79, 1.30]
Baseline Score on Outcome* 1.32 <.001 [1.26, 1.39] 1.34 <.001 [1.27, 1.40] 1.10 <.001 [1.08, 1.12]
SQ (ref. Good SQ, Maintained)
 Bad SQ, Improved 1.00 .99 [0.80, 1.24] 1.01 .91 [0.82, 1.26] 0.73 <.01 [0.57, 0.92]
 Good SQ, Worsened 1.55 <.01 [1.19, 2.01] 1.54 <.01 [1.19, 2.00] 0.69 .02 [0.51, 0.94]
 Bad SQ, Maintained 1.58 <.001 [1.30, 1.93] 1.51 <.001 [1.24, 1.83] 0.86 .15 [0.70, 1.06]
Model Statistics: Model χ2(12) = 181.05
p < .001
Model χ2(12) = 189.01
p < .001
Model χ2(12) = 141.25
p < .001

Note. SQ = Sleep Quality; ARR = adjusted rate ratio; CI = confidence interval; ref. = referent. Bolded results are significant at p < .05 or less. Depressive and anxious symptoms assessed at baseline and 12-month follow-up using the PHQ-2 and GAD-2 (Kroenke et al., 2010).